Table
5: Primary and secondary outcomes based on HBP*
and CBP** at end-point in 284 non-obese patients with type 2 diabetes mellitus.
Outcomes |
Patient
status: HBP* at end-point in 284
non-obese patients |
Patient status:
CBP** at end-point in 284 non-obese patients |
||||||
|
Hypertension
(n = 78) |
Normotension (n = 206) |
Hazard ratio
(95% CI) |
P |
Hypertension
(n = 133) |
Normotension (n = 151) |
Hazard ratio
(95% CI) |
P |
Primary
outcome |
||||||||
Death |
22 |
33 |
2.4
(1.6-5.8) |
0.0008 |
28 |
27 |
1.2
(0.7-2.1) |
0.5803 |
Secondary
outcome |
||||||||
Microvascular
complications |
80 |
22 |
1.8
(1.2-2.0) |
0.0455 |
50 |
52 |
1.1
(0.8-1.7) |
0.3156 |
Macrovascular
complications |
16 |
26 |
0.8
(1.6-6.9) |
0.3763 |
38 |
4 |
4.8
(1.6-5.6) |
0.0009 |
Characteristics
of non-obese patients on HBP and CBP measured at end-point are shown in table
1. The non-obesity was defined by the criteria of Japan Society for the Study
of Obesity. Body mass Index (BMI) with < 25.0 kg/m2 was defined
as non-obesity. The 400 patients in each group were classified as having
non-obesity and hypertension or normotension
according to values of blood pressure as same threshold of normotension
with less than 130 mm Hg of systolic blood pressure measured in the home (HBP*)
and in the clinic (CBP**) at end-point, respectively. Differences in primary
and secondary outcomes for events between non-obese patients with hypertension
or normotension measured at end-point in each group
were assessed using survival curves from the Kaplan-Meier method, and comparisons
were analyzed using hazard ratio by the log-rank
test. CI, confidence interval. Two-tailed values of P < 0.05 were defined as
statistically significant.